
Chinese contract research, development and manufacturing company headquartered in Shanghai and listed on the Hong Kong Stock Exchange under code 2268, formed as a joint venture between WuXi Biologics and WuXi AppTec to serve the bioconjugate market. Provides integrated one stop services for antibody drug conjugates and wider bioconjugates covering antibody and payload linker discovery and development, conjugation process development, analytical and quality work and GMP manufacturing of drug substance and drug product, with facilities in Wuxi and Shanghai and a site in Singapore.
Leave your rating